Amplia Therapeutics Limited (ASX:ATX)
Australia · Delayed Price · Currency is AUD 0.1250
-0.0050 (-3.85%)
At close: Dec 5, 2025
Amplia Therapeutics Company Description
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.
Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer.
It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018.
Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Amplia Therapeutics Limited
| Country | Australia |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Christopher Burns |
Contact Details
Address: 90 William Street Melbourne, 3000 Australia | |
| Phone | 61 3 9123 1140 |
| Website | ampliatx.com |
Stock Details
| Ticker Symbol | ATX |
| Exchange | Australian Securities Exchange |
| Fiscal Year | April - March |
| Reporting Currency | AUD |
| ISIN Number | AU0000023822 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D. | Chief Executive Officer, MD and Director |
| Timothy Luscombe B.Com., C.A. | Chief Financial Officer |
| Rhiannon Jones B.Sc., Ph.D. | Chief Operating Officer |
| Dr. Jason Lickliter MBBS | Chief Medical Officer |
| Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., LLB, MAICD | Company Secretary |